ClinicalTrials.gg
RecruitingNCT02018406Updated Dec 28, 2020

Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury

A Phase 1/2 interventional study of Combination injection of EPO and G-CSF and Injection of normal saline in Neurological Diseases, Ischemic Stroke and Hemorrhagic Stroke, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-12-28.

Sponsored by Yonsei University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 3 months after the study started (first participant enrolled Jul 2011, registered Oct 2013).
  • Started Jul 2011; still recruiting 15 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Ischemic Stroke by Yonsei University — 4 open to participants now, 5 under way, 2 of them phase 3. Ischemic Stroke · Yonsei University.

Started
2011
the only one that year
Phase 1/2
Only one
of the 11
Registered
1st of 11
by date

Among the 11 studies in Ischemic Stroke by Yonsei University, this one is the only one that started in 2011, is the only one in phase 1/2, and was the 1st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

4 of the 11 studies in Ischemic Stroke by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ischemic Stroke by Yonsei University, or all of them as a file.
02

Study summary

The purpose of our study is to determine the safety and efficacy of the combination of erythropoietin (EPO) and granulocyte-colony stimulating factors (G-CSF) in patients with neurological diseases. To be specific, our clinical study is expected that the combination injection of EPO and G-CSF shows neurotrophic and neuroprotective effects by facilitating endogenous repair process in patients with neurological diseases including stroke, cerebral palsy, or atypical parkinsonism. Therefore, we will apply our original treatment technique in patients with neurological diseases, which is expected to overcome current ethical and technical limitations of less evidenced functional recovery, hematological changes, and side effects. Eventually, We will establish a comprehensive clinical background about neurotrophic and neuroprotective effects of this hematopoietic growth factors therapy.

03

Conditions studied

  • Neurological Diseases
  • Ischemic Stroke
  • Hemorrhagic Stroke
  • Cerebral Palsy
  • Atypical Parkinson Disease

Keywords

  • Hematopoietic Growth Factors (EPO, G-CSF),
  • Neurological Diseases,
  • Neurorehabilitation,
  • Neurotrophic and Neuroprotective Effects
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 20 years old
  • Voluntary participants
  • Neurological diseases including stroke, cerebral palsy, or atypical parkinsonism, at least 3 months after their onset
  • Participants who got previous EPO+GCSF injection at least 6 months ago.

Exclusion criteria

Exclusion Criteria:

  • Under 20 years old
  • Participants who can not voluntarily consent
  • Encephalopathy including brain tumor and infection
  • Warfarin (coumadin) medications
  • Leukopenia, Thrombocytopenia, Polycythemia
  • Malignant diseases, Malignant hypertension, Myeloproliferative disorder, Septic embolism, Hyperkalemia
  • Hepatic or Renal dysfunction, Serum creatinine>3mg/dl
  • Allergic reactions against to exogenous EPO and G-CSF
  • Involved in a exclusion criteria for MRI test
  • A women who is pregnant or on breast feeding
  • Body temperature over 38°C
  • Blood pressure over 140/90 mmHg at pre-treatment
  • Blood pressure over 160/100 mmHg during intervention
  • > 15 g/dL at pre-treatment
  • Hb > 17 g/dL during intervention
  • Pneumonia detected by X-ray test
  • Recurrent history of aspiration pneumonia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention

    Intervention Group

    Drug: Combination injection of EPO and G-CSF

  • Placebo comparator
    Control

    Control Group

    Drug: Injection of normal saline

Interventions

  • DrugCombination injection of EPO and G-CSF

    Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.

  • DrugInjection of normal saline

    Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.

06

What researchers measure

Primary outcomes

  1. Vital Sign

    (1) Value of Systolic and Diastolic Blood Pressure, (2) Value of Pulse Rate, (3) Value of Respiratory Rate, (4) Value of Body Temperature. Vital Sign is tested to confirm the safety of the combination of EPO and G-CSF.

    Time frame: 5th day, 30th day during a cycle, and 6 months after pretest

  2. Hematological Test

    (1) Value of Complete Blood Cells at pre-treatment, 5th day, 30th day during a cycle (total three cycles), and 6 months after pretest, (2) Value of Reticulocyte at pre-treatment, 5th day, 30th day during a cycle (total three cycles), and 6 months after pretest, (3) Value of Erythrocyte Sedimentation Rate at pre-treatment, 5th day, 30th day during a cycle (total three cycles), and 6 months after pretest, (4) Value of C-Reactive Protein at pre-treatment, 5th day, 30th day during a cycle (total three cycles), and 6 months after pretest, (5) Value of Electrolyte and Routine Chemistry at pre-treatment, 5th day, 30th day during a cycle (total three cycles), and 6 months after pretest, (6) Value of Prothrombin Time and Activated Partial Thromboplastin Time at pre-treatment, 5th day, 30th day during a cycle (total three cycles), and 6 months after pretest. Hematological Test is tested to confirm the safety of the combination of EPO and G-CSF.

    Time frame: 5th day, 30th day during a cycle, and 6 months after pretest

  3. Chest and Heart Evaluation

    (1) Chest X-ray finding at pre-treatment and 6 months after pretest, (2) Electrocardiography finding at pre-treatment and 6 months after pretest. Chest and Heart Evaluation is tested to confirm the safety of the combination of EPO and G-CSF.

    Time frame: at pre-treatment and 6 months after pretest

Secondary outcomes

  1. Hematological Test

    (1) Value of Erythropoietin Level, (2) Value of CD34+ cells. Value of Erythropoietin Level and CD 34+ Cells are tested to demonstrate the hematological changes and effectiveness of the combination of EPO and G-CSF.

    Time frame: 5th day, 30th day during a cycle, and 6 months after pretest

  2. Physical Assessment

    (1) Score of Muscle Strength with Manual Muscle Testing, (2) Score of Joint Mobility with Range of Motion Test, (3) Score of Muscle Spasticity with Modified Ashworth Scale. Physical Assessment is tested to identify functional recovery of patients by neurotrophic and neuroprotective effects of the combination of EPO and G-CSF.

    Time frame: at pre-treatment, 3 months, and 6 months after pretest

  3. Occupational Assessment

    Score of Activities of Daily Living with Modified Barthel Index, Functional Independence Measure. Occupational Assessments is tested to identify functional recovery of patients by neurotrophic and neuroprotective effects of the combination of EPO and G-CSF.

    Time frame: at pre-treatment, 3 months, and 6 months after pretest

  4. Psychological Assessment

    Score of Psychological Status with Mini-Mental Status Examination, Memory Quotient, Geriatric Depression Scale, if necessary Psychological Assessments are tested to identify functional recovery of patients by neurotrophic and neuroprotective effects of the combination of EPO and G-CSF.

    Time frame: at pre-treatment and 6 months after pretest

  5. Verbal Assessment

    Score of Verbal Function with Aphasia Quotient, Boston Naming Test, Multi-dimensional Voice Performance, if necessary. Verbal Assessments are tested to identify functional recovery of patients by neurotrophic and neuroprotective effects of the combination of EPO and G-CSF.

    Time frame: at pre-treatment and 6 months after pretest

07

Study locations

1 of 1 sites recruiting
  • Department of Rehabilitation Medicine, Yonsei University College of Medicine
    Seoul, 120-752, Korea, Republic of
    Recruiting
08

References and documents

Publications

  • Im SH, Yu JH, Park ES, Lee JE, Kim HO, Park KI, Kim GW, Park CI, Cho SR. Induction of striatal neurogenesis enhances functional recovery in an adult animal model of neonatal hypoxic-ischemic brain injury. Neuroscience. 2010 Aug 11;169(1):259-68. doi: 10.1016/j.neuroscience.2010.04.038. PubMed 20610036 ↗
  • Cho SR, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest. 2007 Oct;117(10):2889-902. doi: 10.1172/JCI31778. PubMed 17885687 ↗
  • Seo JH, Kim H, Park ES, Lee JE, Kim DW, Kim HO, Im SH, Yu JH, Kim JY, Lee MY, Kim CH, Cho SR. Environmental enrichment synergistically improves functional recovery by transplanted adipose stem cells in chronic hypoxic-ischemic brain injury. Cell Transplant. 2013;22(9):1553-68. doi: 10.3727/096368912X662390. Epub 2013 Feb 4. PubMed 23394350 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2011 (actual). Primary completion is estimated for Dec 2025, 173 months after the start.

Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 173 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2013
First posted
Dec 23, 2013
StartActual
Jul 5, 2011
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Dec 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02018406
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Dec 23, 2013
Start date
Jul 5, 2011
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Dec 28, 2020

Study contacts

Sung-Rae Cho, MD
Contact
srcho918@yuhs.ac
82-2-2228-3715

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion